Walker Daniel M, Lefebvre R Craig, Davis Alissa, Shiu-Yee Karen, Chen Sadie, Jackson Rebecca D, Helme Donald W, Oga Emmanuel A, Oser Carrie B, Stotz Caroline, Balvanz Peter, Asman Kat, Holloway JaNae, Lewis Nicky, Knudsen Hannah K
Department of Family and Community Medicine, College of Medicine, The Ohio State University, 700 Ackerman Rd, Suite 4000, Columbus, OH 43202, USA; CATALYST, The Center for the Advancement of Team Science, Analytics, and Systems Thinking in Health Services and Implementation Science Research, College of Medicine, The Ohio State University, 700 Ackerman Rd, Suite 4000, Columbus, OH 43202, USA.
RTI International, 3040 East Cornwallis Road, Research Triangle Park, NC 22709, USA.
J Subst Use Addict Treat. 2024 Mar;158:209276. doi: 10.1016/j.josat.2023.209276. Epub 2023 Dec 22.
To examine differences in perceptions about community stigma towards individuals with opioid use disorder (OUD) between community members involved in the opioid response (i.e., coalition members) and the general public, and how community geography may moderate this relationship.
This study administered identical cross-sectional surveys about perceived community opioid-related stigma to two distinct populations in 66 communities participating in the HEALing Communities Study prior to the intervention period (i.e., coalition members, November 2019-January 2020; residents, March-April 2020). Linear-mixed models compared survey responses of populations, including the moderating effect of community rural/urban location.
A total of 826 coalition members and 1131 residents completed the surveys. The study found no differences between the coalition members and residents for general perceived community opioid-related stigma. In both urban and rural communities, coalition members reported greater perceived community stigma than residents reported towards medication for opioid use disorder (MOUD), naloxone, and drug treatment as an alternative to incarceration.
Our findings suggest similar perceived community opioid-related stigma between coalition members and residents, yet differences emerge related to evidence-based practices (i.e., MOUD, naloxone, and drug treatment as an alternative to incarceration) to reduce opioid overdose deaths.
ClinicalTrials.gov Identifier: NCT04111939.
研究参与阿片类药物应对工作的社区成员(即联盟成员)与普通公众对阿片类药物使用障碍(OUD)患者社区污名化认知的差异,以及社区地理位置如何调节这种关系。
本研究在干预期之前,对参与“治愈社区研究”的66个社区中的两个不同人群进行了关于社区阿片类药物相关污名化认知的相同横断面调查(即联盟成员,2019年11月至2020年1月;居民,2020年3月至4月)。线性混合模型比较了人群的调查反应,包括社区城乡位置的调节作用。
共有826名联盟成员和1131名居民完成了调查。研究发现,联盟成员和居民在总体社区阿片类药物相关污名化认知方面没有差异。在城市和农村社区,联盟成员报告的社区污名化认知均高于居民对阿片类药物使用障碍药物治疗(MOUD)、纳洛酮以及替代监禁的药物治疗的认知。
我们的研究结果表明,联盟成员和居民在社区阿片类药物相关污名化认知方面相似,但在减少阿片类药物过量死亡的循证实践(即MOUD、纳洛酮以及替代监禁的药物治疗)方面存在差异。
ClinicalTrials.gov标识符:NCT04111939。